Ability of lumiliximab to induce ADCC against primary CLL B cells. Lumiliximab does not induce ADCC against CLL B cells. The ability of trastuzumab, alemtuzumab, rituximab, or lumiliximab to mediate ADCC was evaluated using fresh human PBMCs as effector cells and CD19⁺ primary CLL B cells as target cells at the indicated effector/target (E/T) ratios. Mean plus or minus SD of 5 patient samples are shown.